



ATTORNEY'S DOCKET NUMBER: 2002850-0009 (S98-161 US CIP II)

#17  
Amst. C  
attach  
3/12/03

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Fount *et al.*  
Serial No.: 09/728,720  
Filed: December 1, 2000  
For: PREVENTION AND TREATMENT OF HCV INFECTION EMPLOYING  
ANTIBODIES DIRECTED AGAINST CONFORMATIONAL EPITOPES

Examiner: Wortman, D.  
Art Unit: 1648

Assistant Commissioner for Patents  
Washington, DC 20231

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as first  
class mail in an envelope addressed to: Assistant  
Commissioner For Patents, Washington, D.C. 20231  
on February 10, 2003  
*Amst. C*

Sir:

**RESPONSE TO OFFICE ACTION UNDER 37 CFR § 1.111**

In reply to the Examiner's Action that was mailed in the above-referenced case on  
September 10, 2002, Applicant submits the following Amendment and Remarks.

RECEIVED  
FEB 25 2003  
TECH CENTER 1600/2600

**Amendment**

Kindly amend the application as follows. The changes made are illustrated with  
underlining (added text) and brackets (deleted text) in Appendix A (Version with Markings to  
Show Changes Made).

**In the Specification:**

Please replace the paragraph beginning at page 6, line 14, with the following rewritten  
paragraph.

One aspect of the present invention provides monoclonal antibodies, including human  
monoclonal antibodies, which bind to the dominant HCV types in major geographical areas. The  
dissociation constants for these antibodies for their epitopes ranges from less than  $10^{-7}$ M to less

*C.1  
amst.*